BioMed Research International / 2014 / Article / Tab 1

Research Article

Comparison of Commercial Genetic-Testing Services in Korea with 23andMe Service

Table 1

The number of SNPs used for calculation of relative risk in three genetic services.

CategoryThe number of SNPs for all ethnic group (for Asian)Number of overlapping SNPs among services
Hellogene PlatinumDNAGPS Optimus23andMe

Lung cancer1 (1)3 (2)1 (0)0
Esophageal squamous cell cancer2 (2)5 (5)1 (1)2 (Hellogene and DNAGPS)
Colorectal caner1 (1)4 (3)4 (2)2 (DNAGPS and 23andMe)
Bladder cancer1 (1)3 (0)6 (1) for male
7 (2) for female
1 (Three services)
Breast cancer (for female only)1 (1)5 (5)8 (3)1(Hellogene and DNAGPS)
Atopic dermatitis1 (1) 3 (1)5 (1)0
Rheumatoid arthritis1 (1)4 (4)9 (2)1 (DNAGPS and 23andMe)
Systemic lupus erythematosus1 (1)3 (3)6 (4)0
Psoriasis2 (2)4 (4)3 (0)1 (Hellogene and DNAGPS)
Diabetes mellitus, type 11 (1)4 (0)8 (0)0
Body mass index (obesity)1 (1)2 (2)10 (0)1
2
(Three services)
(DNAGPS and 23andMe)
Atrial fibrillation1 (1)2 (0)2 (0)1(Hellogene and DNAGPS)
Coronary artery disease1 (1)7 (4)15 (0)00
Parkinson's disease2 (2)4 (4)10 (4)1
1
(Three services)
(Hellogene and 23andMe)
Narcolepsy1 (1)2 (1)1 (0)0
Warfarin maintenance dose1432(DNAGPS and 23andMe)

Warfarin dosing of Hellogene Platinum was based on GGCX gene genotyping results.
Warfarin dosing of DNAGPS Optimus and 23andMe was based on CYP2C9 and VKORC1 gene genotyping results.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.